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Baseline Post procedure P value
BPA (n[25) CO (L/min) 3.57  0.91 4.44  1.11 0.007
mPAP (mmHg) 39.1  6.9 22.5  4.9 <0.0001
PVR
(dynes/s/cm-5)
746  304 295  117 <0.0001
6MWD (m) 302  100 380  113 0.0004
WHO Fc
(I/II/III/IV)
(0/2/16/7) (10/11/3/0) 0.0009
PEA (n[21) CO (L/min) 3.35  1.20 4.62  1.67 0.007
mPAP (mmHg) 44.6  12.0 23.2  6.2 <0.0001
PVR
(dynes/s/cm-5)
785  291 267  134 <0.0001
6MWD (m) NA NA
WHO Fc
(I/II/III/IV)
(0/1/13/7) (11/7/1/0) 0.0007
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SConclusions: In conclusion, ICE use and high operator volume are signiﬁcant
predictors of improved out come in ASD/PFO closure.
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Background: Left ventricular pseudoaneurysms (LVPAs) may occur as sequelae of
cardiac surgery, myocardial infarction (MI), or endocarditis, and may result in
congestive heart failure (CHF) or rupture with sudden death. Percutaneous closure of
LVPAs has been reported but long-term outcomes are unknown.
Methods:We reviewed all patients who underwent percutaneous LVPA closure at our
center from 09/2008 to 02/2013. All patients had a pre-procedural helical CTA. LVPA
size was measured on CTA in 3 perpendicular planes (x,y, and z), with x-plane being
the largest diameter and y-plane being the largest perpendicular diameter. Clinical
followup was obtained in all patients with assessment of survival and CHF. Followup
CTA studies were reviewed to assess residual LVPA ﬂow.
Results: 15 LVPA closures were performed in 14 patients (mean age 72; male 71%;
CHF 79%, mean NYHA class 2.6). The etiology was post-surgical in 11 cases, post-
MI in 2 cases, and endocarditis in 1 case. 10 had associated paravalvular leaks. The
mean x-plane diameter was 3420mm. Percutaneous access was transapical in 10,
retrograde aortic in 2, and direct chest wall puncture in 2 cases. The LVPA ostium was
closed with Amplazter devices in all cases. Large LVPA sacs were ﬁlled with
embolization coils in 3 patients and thrombin injection in 1 patient. 12 of 14 patients
were alive at mean followup of 717467 days. 1 patient had persistent LVPA ﬂow
requiring a second closure at day 447. He had attempted surgical repair of an LVPA to
bronchial ﬁstula and died intraoperatively at day 448. 1 patient died of progressive
CHF at day 741 after CTA at day 642 had shown no residual LVPA ﬂow. 8 of 12
patients with heart failure had improvement of  1 NYHA class (mean change
-0.81.3). 7 patients had followup CTAs 3 months post procedure (mean 24  17
months). 6 of 7 followup CTAs had no residual ﬂow into the LVPA. 1 patient had
residual LVPA ﬂow after 2 closure procedures.
Conclusions: Percutaneous LVPA closure can be performed safely with durable long-
term results. The majority of patients with heart failure symptoms improve after
closure. Followup CTA imaging demonstrates effective exclusion of LVPA ﬂow in
most cases.
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Background: Pulmonary thromboendarterectomy (PEA) has been a standard therapy
for the treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH),
however, up to 40% of patients are considered non-operable due to distal types of
thromboembolism or comorbidities, resulting in poor prognosis. Therefore, we per-
formed balloon pulmonary angioplasty (BPA) for non-operable patients, and evalu-
ated the efﬁcacy of BPA in comparison with PEA.
Methods: We treated 46 CTEPH patients from November 2001 to May 2013.
Operable 21 patients underwent PEA (56.8  14.7 years old, San-Diego class I:9, II:4,
III:8, IV:0) and 25 non-operable patients, with mean pulmonary artery pressureJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstracts/O(mPAP)  25mmHg in spite of under medical therapy, were performed BPA　(67.8 
10.3 years old, San-Diego class I:0, II:3, III:15, IV:7). BPA was repeated in 1 to 6
sessions to every patient depending on their severity. We evaluated hemodynamics by
Swan-Ganz catheter at baseline and post procedure.
Results: PEA signiﬁcantly improved hemodynamics in operable patients (Table). In
non-operable patients, even BPA dramatically improved hemodynamic parameters
such as a signiﬁcant increase in cardiac output (CO) and decrease in mPAP and
pulmonary vascular resistance (PVR), which were accompanied with improved 6-
minute walk distance (6MWD) and WHO-Fc as observed in PEA for operable
patients. Reperfusion pulmonary injury occurred in 3 patients (14.3%) after PEA, and
in 21 sessions (32.8%) after BPA with 3 sessions required emergent intubation. Two
patients (9.5%) died after PEA due to persistent of right heart failure and 1 patient
(4.0%) died after BPA due to systemic infection.Conclusions: BPA could be an effective treatment option for non-operable CTEPH to
achieve dramatic improvement of hemodynamic and outcome parameters. The efﬁ-
cacy and safety for non-operable cases were equivalent to those of PEA for operable
cases.
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Background: Critical aortic stenosis (AS) in utero is a severe disease that may evolve
to hypoplastic left heart syndrome (HLHS) if not treated. Fetal aortic valvuloplasty
(AV) has been performed in selected cases to avert this progression. However, more
data is required to assess its impact on achieving a biventricular circulation (BVC),
especially in patients with smaller left ventricles (LV). We report the immediate
procedural results and the postnatal outcomes up to one year of age of fetuses who
underwent AV.
Methods: Procedures were performed under spinal maternal block and fetal anes-
thesia between 23 to 34 weeks gestation through a transabdominal (maternal) and
transthoracic (fetus) approach under echo guidance. The LV apex was entered using
17/18 G Chiba needles and the valve was dilated with coronary angioplasty
balloons (1-1.2 times the valve annulus). Serial echos were performed pre and post
natally.
Results: Thirteen fetuses underwent the procedure. Five were severely hydropic,
4 had severe mitral regurgitation and gigantic left atrium (GLA), 3 had hypoplastic
LVs (2 severe). Endocardial ﬁbroelastosis was present in all (severe in 6). In all but 1
fetus the valve was successfully crossed and dilated. Satisfactory antegrade ﬂow was
observed in 12 cases, aortic insufﬁciency in 7 and pericardial effusion  bradycardia
in 9 fetuses requiring needle aspiration + atropine. There were no maternal compli-
cations. There were 2 early neonatal deaths after premature delivery because of severe
hydrops (both with GLA). BVC was achieved in 3 neonates. All required aortic
valvuloplasty. Three with smaller LV underwent aortic valvuloplasty + hybrid
procedures, with 2 undergoing LV overhaul and a BVC @ 9 months of age. In the
other a BVC is still contemplated. One neonate born at another institution died on
the ﬁrst day of life, 3 were managed as univentricular hearts and 1 had comfort care
(no LV growth).
Conclusions: Fetal aortic valvuloplasty may improve overall neonatal and infancy
outcomes. BVC was achieved in 30% of the cases with a chance of improving to
a 50% rate. Neonatal outcomes seem to depend on the clinical and anatomical fetal
presentation, with hydropic fetuses having worse outcomes.RAL/Percutaneous Treatment of Non-valvular Structural Heart Disease B33
